Top Injectable Manufacturer in Eritrea – Reliable Pharmaceutical Solutions
- Maulik Sudani
- 1 day ago
- 11 min read
Last Updated: August 28, 2026
TL;DR: Eritrea is one of the least documented medicines markets in the world, and the honest starting point is to say so. There is essentially one paragraph of public description of how medicines are registered there – an undated summary on the African Medicines Regulatory Harmonisation country page – and it tells you two useful things: a first submission to the National Medicines and Food Administration is treated as a new application, and a manufacturer whose site the regulator has not previously inspected and approved must submit a Site Master File, with a GMP inspection possible. Dossier format, certificate requirements, fees, validity and timelines are not published anywhere we could reach. Structurally the market is simple: PHARMECOR, the state pharmaceutical and medical supplies corporation, imports and distributes – 85% to Ministry of Health facilities and 15% to other public institutions and private pharmacies in the first half of 2025 – and the Ministry of Health is the sole Global Fund Principal Recipient on every grant since 2003. The binding constraint is not regulatory. It is payment: the Nakfa is not convertible and the National Bank of Eritrea must approve every cross-border transfer.
Key Takeaways
The registration requirements are not published, and your first deliverable is a letter, not a dossier. The only public description of the National Medicines and Food Administration's process states that a first application is treated as a new application, that medicines from facilities the regulator has not previously inspected and approved require a Site Master File, and that the regulator may also conduct a GMP inspection. Beyond that – whether CTD or ACTD is expected, whether a WHO certificate of a pharmaceutical product or a GMP certificate is required, what samples or fees are needed, how long a review takes and how long an approval lasts – nothing is published. Even the regulator's name appears in three different forms in Eritrean government output. Any supplier who quotes you a confident Eritrean dossier checklist is quoting something they cannot source.
There is one documented counterparty. PHARMECOR, the Pharmaceutical and Medical Supplies Corporation of Eritrea, imports and distributes medicines, and the Ministry of Information reports that it distributed 351 million Nakfa of medicines and equipment in the first half of 2025, 85% to Ministry of Health facilities and 15% to other government institutions and private pharmacies, having distributed 606 million Nakfa in 2023 on a 79/21 split. It states that it imported over US$32 million of supplies in 2023 and over US$8 million in the first half of 2025, and that technical, quality and financial inspections are carried out with the national regulator both before procurement and before items enter service. Whether any private import channel exists in law is not documented either way.
Payment is the real risk, and it should be priced before the product is. The United States Department of State's investment climate reporting records that the Nakfa is not convertible, that the exchange rate is set by government and does not fluctuate, that the National Bank of Eritrea must approve and manage all fund transfers into and out of the country and can decline them, that foreign banks may not operate in Eritrea, and that organisations have found it difficult to move foreign currency even to pay essential bills abroad. It also records that public procurement policies are not publicised and the national budget is not public. For an exporter this converts a market-entry question into a counterparty and settlement question.
The donor channel is where the volume and the timing are. The Global Fund has financed ten grants in Eritrea since 2003 and the Ministry of Health is the Principal Recipient on all of them; the three active grants covering HIV, tuberculosis and malaria carry signed amounts of roughly US$117.3 million, US$28.8 million and US$87.6 million respectively and are currently scheduled to run to 31 December 2026, with the next-cycle funding requests submitted in May 2023. On the product side WHO's 2024 Eritrea malaria profile records injectable artesunate as the national treatment for severe malaria, adopted in 2015, with 71% of the population living in high-transmission areas and around 220,000 estimated cases a year. A supplier who wants to be relevant to the next cycle needs to be visible now.
Introduction: Why Eritrea Demands a Premium Injectable Manufacturer in Eritrea
Eritrea is a market of roughly 3.6 million people – the World Bank puts the 2025 population at 3,607,003 – with a health system operating on very little money. Current health expenditure was US$28.30 per person in 2023 on the World Bank's estimate, and the Bank's last observation for gross national income per capita is US$650, recorded for 2011; there is no observation for any year since. That absence is itself a fact worth stating, because it tells you how much of what you will read about Eritrea is estimate rather than measurement. What the health data does show is a system delivering more than its budget suggests: immunisation coverage with three doses of DPT has held at 95% across 2022, 2023 and 2024, life expectancy was 68.9 years in 2024, and maternal mortality fell from 363 per 100,000 live births in 2018 to 291 in 2023. Tuberculosis incidence was 115 per 100,000 in 2024 and HIV prevalence among adults 0.4%.
The injectable demand profile follows directly from that. WHO's Eritrea malaria profile of December 2024, with data validated by the country in November 2024, records injectable artesunate as national policy for severe malaria since 2015, 71% of the population living in high-transmission areas, an estimated 220,000 cases and 459 deaths in 2023, and pyrethroid resistance confirmed at every site tested. Add maternal health, anaesthesia, anti-infectives and a routine immunisation programme running at 95% coverage, and the shape of the requirement is clear enough. What is not clear – and this is the honest difficulty of writing about Eritrea – is the procedure by which a foreign manufacturer becomes an approved supplier of those products. The rest of this article separates what is documented from what is not, because for this market that distinction is more valuable than any amount of confident-sounding guidance.
What Sets a World-Class Injectable Manufacturer in Eritrea Apart
Start with what is actually established. Eritrea's medicines regulator sits within the Ministry of Health and is most commonly referred to as the National Medicines and Food Administration, although Eritrean government publications have also called it the National Food and Medicine Safety Control and the National Food and Medicines Control; we have not found an instrument settling which is the current statutory name, and we are not going to pretend otherwise. The African Medicines Regulatory Harmonisation country profile states plainly that there has been no national health act or overarching regulation in Eritrea, but that there are several proclamations covering the control of drugs, cosmetics and sanitary items among other subjects. Those proclamations are referred to without number, date or link, and no Eritrean government gazette is available online. So the legal basis of medicines control exists and is referenced by a continental body, but its text is not publicly obtainable.
What that profile does give you is the two operative requirements, and they happen to be the two a serious manufacturer can prepare for in advance. An application submitted to the regulator for the first time is handled as a new application, and medicines from a manufacturing facility the regulator has not previously inspected and approved must be accompanied by a Site Master File, with the regulator reserving the right to conduct a GMP inspection. That is a facility-level gate, not a paperwork gate, and it is the reason the practical order of work for Eritrea is inverted compared with most markets: prepare the Site Master File and the inspection readiness of the site first, then write to the regulator, and only then build the product dossier to whatever format the answer specifies. It is worth adding that Eritrea has neither signed nor ratified the African Medicines Agency treaty and does not appear on WHO's published list of regulators operating at maturity level 3 or 4, so there is no regional or reliance shortcut to substitute for that direct enquiry. Nor should anyone assume the neighbouring Ethiopian requirements apply: they are a different regulator under different law, and the substitution is the single most common error in published commentary about Eritrea.
Quality Systems Behind Every Injectable Supplied to Eritrea
When a regulator's published requirements are thin, the manufacturer's own quality system carries proportionally more of the burden of proof – and a Site Master File that may be tested by inspection is exactly the document that exposes whether that system is real. Farbe Firma manufactures under WHO-GMP certification in Gujarat, India, with aseptic filling in ISO Class 5 conditions, and maintains the full evidential chain behind every batch: assay and related substances by HPLC, residual solvents by GC, bacterial endotoxins by LAL, water content by Karl Fischer, container closure integrity, and media fills and environmental monitoring records that an inspector can follow from the room to the batch. Stability is generated under ICH Q1A(R2) and Q1B on conditions appropriate to the destination climate rather than adapted from temperate data, which matters for a Red Sea coastal supply chain.
The second half of quality in a market like this one is documentary discipline about uncertainty. We will tell a customer for Eritrea exactly what we have verified and what we have not, in writing, and we will not manufacture a dossier to a format nobody has specified. Our files are maintained in CTD and ACTD structure and can be issued in either, with a WHO-format certificate of a pharmaceutical product, GMP certification, free sale documentation and per-product certificates of analysis available on request, so that whichever combination the regulator or PHARMECOR asks for can be produced quickly rather than assembled from scratch. Where a molecule is bound for a Global Fund or United Nations financed programme we can also discuss the additional documentation those channels typically expect, while being clear that we have not verified which procurement mechanism Eritrea's grants use.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Injectable Manufacturer in Eritrea for Global Buyers
Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO in Gujarat, India, exporting to more than 30 countries, and India is already a materially large supplier to this market. India's own reported exports of pharmaceutical products under HS Chapter 30 to Eritrea were about US$4.09 million in 2023, US$4.43 million in 2024 and US$3.40 million in 2025. Set against the Indian Ministry of External Affairs' figure of US$10.05 million for total Indian exports to Eritrea in the 2023-24 financial year, pharmaceuticals are roughly two-fifths of the entire bilateral export basket, and the Ministry names them first among goods exported. Eritrea does not report to UN Comtrade, so every one of those figures is India's own reported data rather than a two-sided reconciliation, and we present it as such.
We are also realistic about how this market is entered. There is no distributor network to appoint and no tender portal to monitor: PHARMECOR is the documented importer and distributor, the Ministry of Health is the Principal Recipient on every Global Fund grant Eritrea has received since 2003, and the national regulator sits alongside PHARMECOR in the inspection process both before procurement and before items are released into service. That is a short list of counterparties, and it means the work is relationship and documentation rather than distribution build-out. It also means commercial terms deserve as much attention as technical ones, given a non-convertible currency, a government-set exchange rate and a central bank that must approve every transfer. We would rather have that conversation with a buyer at the quotation stage than discover it at the settlement stage, and we structure terms accordingly.
What we bring to a market this thinly documented is manufacturing depth and candour in equal measure. More than 100 sterile injectable presentations across anti-infectives, analgesia and anaesthesia, oncology support, and critical-care and maternal-health molecules, filled on ISO Class 5 lines under WHO-GMP certification, with IP, USP, BP and EP monograph compliance and full CTD and ACTD dossier capability. Own-label and contract manufacturing are available for buyers who need product under their own brand. There is no India-Eritrea pharmaceutical or health memorandum of understanding – the Indian Ministry of External Affairs' own bilateral brief lists every instrument in force and none is in this sector – so nothing here rests on an intergovernmental arrangement. It rests on a manufacturer that can pass an inspection, document what it claims and say plainly what it does not know. To discuss a molecule, a tender line or a Site Master File submission, write to director@farbefirma.org.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
What does it take to register a medicine in Eritrea?
Honestly, the requirements are not published. The only public description of the process states that an application submitted to the National Medicines and Food Administration for the first time is treated as a new application, and that medicines from manufacturing facilities not previously inspected and approved by the regulator must submit a Site Master File, with a GMP inspection possible. Whether a CTD or ACTD dossier is expected, whether a WHO certificate of a pharmaceutical product or a GMP certificate is mandatory, what samples or fees apply, how long review takes and how long an approval lasts are not stated in any source we could reach, and no Eritrean gazette or regulator website is available online. The practical first step is a written enquiry to the regulator, with your Site Master File already prepared.
Who imports medicines into Eritrea?
PHARMECOR, the Pharmaceutical and Medical Supplies Corporation of Eritrea, is the documented importer and distributor. Eritrean Ministry of Information reporting states that it distributed 351 million Nakfa of medicines and equipment in the first half of 2025, 85% to Ministry of Health facilities and 15% to other government institutions and private pharmacies, and 606 million Nakfa in 2023 on a 79/21 split; that it imported over US$32 million of supplies in 2023 and over US$8 million in the first half of 2025; and that technical, quality and financial inspections are conducted with the national regulator before procurement and again before items are put into service. Whether a private company may hold an import licence in its own right is not documented either way, so we do not assert that importation is legally monopolised – only that all documented importation runs through PHARMECOR.
Is there local pharmaceutical manufacturing in Eritrea?
There is some domestic production. PHARMECOR distributes 35 types of medicines produced by Azel Pharmaceutical Share Company, and Ministry of Information reporting groups Azel with an oxygen plant and an eyeglass enterprise when totalling domestic output. Beyond that we will not go: Azel's ownership, founding date, location, certifications and product range are described inconsistently across sources and we could not open the company's own site, so we do not assert whether Azel manufactures sterile injectables. Whether any sterile injectable is made in Eritrea at all is, for an exporter, the single most commercially relevant unknown, and it is genuinely unknown.
How is medicine supply financed in Eritrea?
Substantially through donor grants alongside the state. The Global Fund has financed ten grants since 2003 and the Ministry of Health is the Principal Recipient on all of them, with no separate United Nations or civil-society recipient. The three active grants cover HIV, tuberculosis and malaria with signed amounts of approximately US$117.3 million, US$28.8 million and US$87.6 million, all currently scheduled to end on 31 December 2026, and the next-cycle funding requests were submitted in May 2023. We have not verified the allocation for the next cycle or which procurement mechanism those grants use, so we do not state either. Domestically, health expenditure was estimated at US$28.30 per person in 2023, and the national budget is not published.
What makes Farbe Firma a suitable injectable manufacturer for Eritrea?
Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO in Gujarat, India, filling on ISO Class 5 aseptic lines and exporting to more than 30 countries. For Eritrea specifically the decisive capability is inspection readiness: because the one published requirement is a Site Master File for previously uninspected sites with a possible GMP inspection, we maintain a current Site Master File and the supporting evidence behind it – HPLC and GC release testing, LAL endotoxin control, Karl Fischer moisture determination, media fills, environmental monitoring and ICH Q1A(R2) and Q1B stability generated on conditions appropriate to the destination climate. We prepare CTD and ACTD dossiers, can issue WHO-format certificates of a pharmaceutical product, GMP and free sale documentation on request, and offer own-label and contract manufacturing. Contact director@farbefirma.org to discuss a specific molecule, tender line or own-label programme.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments